

NEUROBIOLOGICAL MECHANISMS AND MODERN TREATMENT APPROACHES IN DEPRESSIVE DISORDERS

<https://doi.org/10.5281/zenodo.18210687>

Rahimov Alisher Akmaljon o'g'li

Fergana Public Health Medical Institute

Assistant

Abstract

Depressive disorders are among the most common and debilitating mental health conditions, characterized by emotional, cognitive, and functional impairments. Recent advances in neuroscience indicate that depression is a multifactorial disorder involving complex neurobiological mechanisms. This article examines the key neurobiological processes underlying depressive disorders, including monoaminergic dysfunction, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, neuroinflammation, and impaired neuroplasticity. In addition, modern treatment approaches such as pharmacotherapy, psychotherapy, and neuromodulation techniques are reviewed. Understanding these mechanisms provides a scientific foundation for developing effective, individualized treatment strategies and improving clinical outcomes in depressive disorders.

Keywords

Depressive disorders, neurobiology, monoamine hypothesis, HPA axis, neuroinflammation, neuroplasticity, antidepressant treatment, neuromodulation.

INTRODUCTION

Depressive disorders represent one of the most prevalent and disabling mental health conditions worldwide, significantly affecting emotional well-being, cognitive functioning, and overall quality of life. According to contemporary psychiatric research, depression is not solely a psychological phenomenon but a complex disorder involving multiple neurobiological mechanisms. Understanding the neurobiological basis of depressive disorders is essential for developing effective and personalized treatment strategies. This article aims to explore the key neurobiological mechanisms underlying depressive disorders and to review modern therapeutic approaches used in clinical practice.

Neurobiological mechanisms of depressive disorders.

The pathophysiology of depressive disorders involves dysregulation across several interconnected neurobiological systems. One of the most established mechanisms is the monoamine hypothesis, which suggests that depression is

associated with decreased availability of neurotransmitters such as serotonin, norepinephrine, and dopamine. These neurotransmitters play a critical role in mood regulation, motivation, and emotional processing.

In addition to monoaminergic dysfunction, hypothalamic–pituitary–adrenal (HPA) axis dysregulation is frequently observed in individuals with depression. Chronic stress leads to prolonged activation of the HPA axis, resulting in elevated cortisol levels, which can negatively affect neuronal plasticity and hippocampal function. Structural and functional brain changes, particularly reduced hippocampal volume and altered activity in the prefrontal cortex and amygdala, have been consistently reported in neuroimaging studies of depressed patients.

Another important mechanism involves neuroinflammation. Increased levels of pro-inflammatory cytokines have been found in patients with depressive disorders, suggesting that immune system activation may contribute to the development and persistence of depressive symptoms. Furthermore, impaired neuroplasticity and reduced neurogenesis, especially in the hippocampus, are believed to play a crucial role in the cognitive and emotional symptoms of depression.

Neurobiological Mechanism	Pathophysiological Features	Associated Symptoms	Modern Treatment Approaches
Monoaminergic dysfunction	Reduced levels of serotonin, norepinephrine, and dopamine	Depressed mood, anhedonia, low motivation	SSRIs, SNRIs, tricyclic antidepressants, atypical antidepressants
HPA axis dysregulation	Chronic stress, elevated cortisol levels	Fatigue, sleep disturbances, emotional instability	Antidepressants, stress management, psychotherapy
Neuroinflammation	Increased pro-inflammatory cytokines (IL-6, TNF- α)	Cognitive impairment, psychomotor slowing	Anti-inflammatory strategies, antidepressants, lifestyle modification
Impaired neuroplasticity	Reduced BDNF levels, decreased hippocampal neurogenesis	Memory deficits, emotional dysregulation	Antidepressants, ketamine, cognitive-behavioral therapy
Structural and functional brain changes	Altered activity in prefrontal cortex, hippocampus, amygdala	Impaired decision-making, emotional reactivity	Neuromodulation (ECT, TMS), psychotherapy
Glutamatergic system dysfunction	NMDA receptor dysregulation	Treatment-resistant	Ketamine, esketamine, novel

		depression, severe symptoms	glutamate modulators
--	--	-----------------------------	----------------------

Modern treatment approaches.

Modern treatment strategies for depressive disorders are based on a biopsychosocial model and include pharmacological, psychological, and neurostimulation-based interventions. Antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants, remain the first-line pharmacological treatments. These medications aim to restore neurotransmitter balance and improve synaptic plasticity.

Psychotherapy, particularly cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), and mindfulness-based approaches, has demonstrated strong efficacy in treating depressive disorders. These therapies help patients modify maladaptive thought patterns, improve emotional regulation, and enhance coping strategies.

In treatment-resistant cases, neuromodulation techniques have gained increasing attention. Methods such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS) have shown promising results by directly targeting dysfunctional neural circuits. Additionally, emerging treatments, including ketamine and esketamine therapy, offer rapid antidepressant effects and represent a significant advancement in modern psychopharmacology.

Conclusion

Depressive disorders are complex conditions rooted in multifactorial neurobiological mechanisms involving neurotransmitter imbalance, stress-related neuroendocrine dysfunction, neuroinflammation, and impaired neuroplasticity. Advances in neuroscience have significantly enhanced our understanding of these mechanisms, leading to the development of more effective and diverse treatment approaches. A comprehensive and individualized treatment strategy that integrates pharmacotherapy, psychotherapy, and modern neuromodulation techniques is essential for improving clinical outcomes and enhancing the quality of life for individuals with depressive disorders.

REFERENCES:

1. American Psychiatric Association. DSM-5: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: APA Publishing, 2013.

2. Nestler E. J., Barrot M., DiLeone R. J., Eisch A. J., Gold S. J., Monteggia L. M. Neurobiology of depression. *Neuron*, 2002, 34(1), 13–25.
3. Malhi G. S., Mann J. J. Depression. *The Lancet*, 2018, 392(10161), 2299–2312.
4. Krishnan V., Nestler E. J. The molecular neurobiology of depression. *Nature*, 2008, 455, 894–902.
5. Duman R. S., Aghajanian G. K. Synaptic dysfunction in depression: potential therapeutic targets. *Science*, 2012, 338(6103), 68–72.
6. McEwen B. S. Stress, adaptation, and disease: Allostasis and allostatic load. *Annals of the New York Academy of Sciences*, 1998, 840, 33–44.
7. Miller A. H., Raison C. L. The role of inflammation in depression. *Nature Reviews Immunology*, 2016, 16, 22–34.
8. Гуломкодиров, М. (2023). ДЛИТЕЛЬНЫЕ СТАДИИ ПОЗДНЕЙ ШИЗОФРЕНИИ РЕМИТТИРУЮЩЕГО ТИПА. O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIY TADQIQOTLAR JURNALI, 2(19), 349-355.
9. Muzaffar, G. (2023). Features of Reactive Psychosis in Schizophrenia. *Research Journal of Trauma and Disability Studies*, 2(1), 44-49.
10. Muzaffar, G. (2023). Modern Concepts About Schizophrenia. *Eurasian Medical Research Periodical*, 16, 37-41.
11. Гуломкодиров, М., & Машрапов, Ж. (2022). Эмпирический поиск взаимосвязи когнитивного функционирования и общеклинической картины у больных шизофренией. *Theoretical aspects in the formation of pedagogical sciences*, 1(5), 221-223.
12. Долимова, М. А., Аграновский, М. Л., Солиев, Д. М., & Гуломкодиров, М. М. (2022). Роль поддерживающей терапии в сравнительной эффективности качества и структуры ремиссий при рецидивной шизофрении. *Искусство медицины. Международный медицинский научный журнал*, 2(1).
13. Аграновский, М. Л., Гуломкодиров, М. М., Далимова, С. А., & Муминов, Р. К. (2022). Анализ данных отдалённого катамнеза при шизофрении с ремиттирующим типом течения. *Экономика и социум*, (6-2 (97)), 285-288.
14. Аграновский, М. Л., Гуломкодиров, М. М., Муминов, Р. К., & Далимова, С. А. (2022). Отдаленный этап шизофрении с ремиттирующим типом течения и расстройств шизофренического спектра. *Экономика и социум*, (6-2 (97)), 289-292.

15. Гуломқодиров, М. (2021). Юрак-қон томир касалликлардаги депрессия холатини ташхислаш ва даволашни такомиллаштириш. *Интернаука*, (17-4), 61-62.
16. Гуломқодиров, М. (2021). Афъюнга қарамлик хосил бўлиш динамикаси ва хусусиятлари. *Интернаука*, (20-7), 23-25.
17. Muzaffar, G. U. (2024). IJOBIY VA SALBIY SINDROMLAR SHKALASI (PANSS). SO 'NGI ILMIIY TADQIQOTLAR NAZARIYASI, 7(2), 147-149.
18. Muzaffar, G. U. (2024). NICOTIN THERAPY. *IMRAS*, 7(1), 798-799.
19. Maxmit o'g, G. U. M. (2023). APATIK DEPRESSIYA: TUZILISHI VA DINAMIKASI. O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIIY TADQIQOTLAR JURNALI, 2(24), 226-229.
20. Музаффар, Ғ. (2023). БОҒЧА ЁШИДАГИ БОЛАЛАРДА БИЛИШ ЖАРАЁНЛАРИНИНГ РИВОЖЛАНИШИ. THEORY AND ANALYTICAL ASPECTS OF RECENT RESEARCH, 2(20), 26-29.
21. Muzaffar, G. (2023). Family Approach in PsychoCorrection of Disorders Identities of Patients with Schizophrenia. *Eurasian Medical Research Periodical*, 20, 243-247.
22. Dolimova, M. A., Agranovsky, M. L., Soliyev, D. M., & Gulomkodirov, M. M. (2022). The role of maintenance therapy in comparative effectiveness of the quality and structure of remissions in recurrent schizophrenia. *Art of Medicine. International Medical Scientific Journal*, 2(1).
23. G'ulomqodirov, M. M. (2024). REMITTIRLASHGAN TIPDAGI KECHUVCHI SHIZOFRENIYANING UZOQ BOSQICHLARI: TIPOLOGIYASI, KLINIKO-PSIXOPATOLOGIK XUSUSIYATLARI, PROGNOZI, PROFILAKTIKASI. *IMRAS*, 7(6), 383-386.
24. Maxmit o'g, G. U. M. (2025). NEVROTIK DEPRESSIYA: KLINIK KO 'RINISHLAR, OLDINI OLISH VA DAVOLASH CHORALARI. O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIIY TADQIQOTLAR JURNALI, 3(36), 220-222.
25. Muzaffar, G. U. (2025). SHIZOFRENIYA KASALLIGI HAMDA UNING KELIB CHIQUISH SABABLARI. *PEDAGOGICAL SCIENCES AND TEACHING METHODS*, 4(41), 83-85.
26. Ibodullayevich, F. N., Al-Hussainy, A. F., H Tizkam, H., AbdulHussein, A. H., Salah, O. H., Edan, R. T., ... & Kamola Muminovna, A. (2024). Exploiting pH-Sensitive Polymer Micelles Nanoparticles for Paclitaxel Delivery and Tumor Suppression: Advanced Targeted Cancer Therapy. *Journal of Nanostructures*, 14(3), 945-952.

27. G'ulomqodirov, M. M., & Muradimova, A. R. (2025). INSULTDAN KEYINGI DEPRESSIV SINDROMNI KLINIK KO'RINISHI. Журнал гуманитарных и естественных наук, (24), 39-45.
28. Maxmit o'g, G. U. M. (2025). ALZGEYMER KASALLIGI: KLINIK-XUSUSIYATLARI, DIAGNOS TIZIMI VA DAVOLASHGA YONDASHUVLAR. O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIY TADQIQOTLAR JURNALI, 4(40), 320-323.
29. Maxmit o'g, G. U. M. (2025). REAKTIV DEPRESSIYA: KLINIK KO'RINISHLAR, SABABLARI VA DAVOLASH. INNOVATIVE DEVELOPMENTS AND RESEARCH IN EDUCATION, 3(35), 205-207.
30. Soyibjono'g, A. G. A. TYPOLOGY OF ANXIETY-PHOBIC DISORDERS.
31. Rakhmatova, M., Shakhanova, S., Nazarova, J., Azizova, F., Astanakulov, D., Akramov, G., & Mirametova, N. (2024). Brain tumor information retrieval system for brain tumor diagnosis. Health Leadership and Quality of Life, (3), 10.
32. NN, D., Usmnova, M. B., Kozimjonova, I. F., Qayumjonov, O. Z., & Akramov, G. S. SOCIAL PARAMETERS CHARACTERIZING PERSONALITIES OF PATIENTS WITH INCOMPLETE SUICIDES.